Neuro-Optometric Rehabilitation — The TBI Vision Crisis No One Is Talking About

Sixty-nine million traumatic brain injuries happen every year worldwide. Ninety percent of those patients will experience visual dysfunction. The market to treat them barely exists.

In March 2021, the US Department of Defense published a finding that should have rewritten the playbook for traumatic brain injury care: blast-injured service members experience visual impairment at 2.5 times the rate of non-blast TBI patients, with 52 percent reporting vision loss compared to 20 percent in civilian TBI populations. The military had discovered, through the hard arithmetic of combat injuries, what neuro-optometry had been saying for decades — that traumatic brain injury is, in the majority of cases, a vision problem.

The civilian healthcare system has been slower to learn the same lesson. And the cost of that slowness — measured in undiagnosed patients, delayed recoveries, and a treatment market that is a fraction of what demand warrants — represents one of the largest unmet opportunities in vision care.

The Scale of the Problem

The numbers are staggering and well-documented. The World Health Organization, drawing on a 2018 systematic review published in the Journal of Neurosurgery, estimates that 69 million individuals sustain a traumatic brain injury annually worldwide. In the United States alone, the CDC reports approximately 2.8 million TBI-related emergency department visits, hospitalizations, and deaths each year. An additional 1.6 to 3.8 million sports-related concussions occur annually, many of which go unreported. More than 50,000 Americans die from TBI-related causes every year, making it a leading cause of disability and death.

A 2024 meta-analysis found that 18.2 percent of US adults — roughly one in five — report a lifetime history of traumatic brain injury. This is not a rare condition. It is an epidemic hiding in plain sight behind the more dramatic statistics of the injuries that cause it.

Now apply the visual dysfunction rate. Clinical literature consistently reports that 80 to 90 percent of TBI patients experience some form of visual disturbance: convergence insufficiency, accommodative dysfunction, saccadic impairment, visual field deficits, light sensitivity, double vision, or difficulty tracking moving objects. The Neuro-Optometric Rehabilitation Association and multiple peer-reviewed studies place the figure at approximately 90 percent for patients who receive comprehensive visual assessment.

That means roughly 2.5 million Americans sustain a brain injury with visual consequences every single year. Most of them will never see a neuro-optometrist.

A Market Defined by What It Is Missing

The neuro-optometric rehabilitation market is difficult to size precisely because it barely exists as a formal market category. Unlike amblyopia treatment or sports vision training, there is no standalone market research report that tracks neuro-optometric rehabilitation revenue. The field lives in the margins between neurology, ophthalmology, optometry, and rehabilitation medicine — and falls through the cracks of each.

But the addressable opportunity can be estimated from first principles. If 2.52 million Americans per year experience TBI-related visual dysfunction, and the average cost of a vision therapy treatment program ranges from $2,762 to $3,982 per patient (based on provider surveys and published fee schedules), the total addressable US market is between $7 billion and $10 billion annually.

The actually served market is a sliver of that figure. Estimates suggest that only 5 to 10 percent of TBI patients with visual symptoms receive neuro-optometric rehabilitation. At $348 million to $1 billion in treated patients, the gap between what exists and what should exist is enormous — roughly a ninefold underservice.

The broader concussion treatment market provides context. Valued at $6.58 billion in 2024 and projected to reach $9.31 billion by 2030, the overall TBI treatment ecosystem is growing. Vision therapy's share of that pie is expanding but remains disproportionately small relative to the prevalence of visual symptoms.

Why Patients Are Not Getting Treated

Three structural barriers explain the gap between need and treatment.

The diagnostic gap. Visual symptoms after TBI are frequently overlooked during initial and even follow-up care. Emergency rooms focus on ruling out life-threatening injuries. Neurologists assess cognitive and motor function. Primary care physicians check for post-concussion syndrome. But comprehensive binocular vision assessment — the kind that catches convergence insufficiency, accommodative dysfunction, and oculomotor impairment — is not part of standard TBI protocols in most healthcare systems.

Visual problems may not present immediately after injury. Symptoms often emerge weeks or months later, when the acute care team has moved on and the patient is left managing vague complaints that do not fit neatly into any specialist's lane. "I can't focus on my computer anymore" gets attributed to fatigue or anxiety. "I keep losing my place when reading" gets chalked up to brain fog. The vision component is real, measurable, and treatable — but it requires someone to think to look for it.

The provider shortage. The Neuro-Optometric Rehabilitation Association and the College of Optometrists in Vision Development represent the core professional communities in this space, but their combined membership is small relative to the patient population. Neuro-optometric rehabilitation requires specialized fellowship training beyond standard optometry education. There are simply not enough qualified providers to serve 2.5 million new patients per year, even if every patient were correctly diagnosed and referred.

The geographic distribution is equally challenging. Neuro-optometrists cluster in metropolitan areas and academic medical centers. A TBI patient in rural Montana or south Georgia may be hours from the nearest qualified provider. Telehealth has made initial consultations more accessible, but the hands-on nature of vision therapy — prism prescriptions, in-office training with specialized equipment, progressive loading of neural circuits — limits how much can be done remotely.

The insurance barrier. This is the most consequential constraint. The Veterans Administration covers neuro-optometric rehabilitation for service-connected TBI — a policy that reflects both the VA's recognition of blast-related visual dysfunction and its self-funded payer model that can absorb higher upfront costs when long-term outcomes justify them. Private insurance, however, largely does not cover vision therapy for TBI patients, despite the clinical evidence.

The irony is bitter. All 50 states now have concussion laws requiring removal of athletes from play after suspected concussion and medical clearance before return. These laws have dramatically increased TBI awareness, screening, and initial diagnosis. But they have not created a corresponding treatment pathway for the visual dysfunction that accompanies most of these injuries. We are getting much better at identifying the problem. We are not getting better at treating it.

The Evidence Base Is Stronger Than You Think

The 2019 report from the Journal of Disability and Rehabilitation, reviewing outcomes for 3,000 post-mild TBI patients who underwent neuro-optometric rehabilitation, found the therapy effective for improving oculomotor function, reducing symptoms, and supporting return to work and daily activities. Office-based, home-based, or combination therapy programs with durations of 8 to 12 weeks and frequencies of 2 to 5 sessions per week showed measurable improvement across multiple outcome measures.

NFL and military medical center concussion protocols now routinely include vision assessment. The Defense and Veterans Eye Injury and Vision Registry tracks visual outcomes across the military healthcare system, generating a dataset that has helped establish the evidence base for post-TBI vision therapy in ways that civilian healthcare research has been slower to replicate.

The clinical evidence is not the problem. The problem is translating evidence into standard-of-care practice across a fragmented healthcare system where neurologists, emergency physicians, primary care providers, and optometrists rarely coordinate on TBI visual recovery.

What Unlocks This Market

The neuro-optometric rehabilitation market will not grow incrementally. It will inflect when several tipping points converge.

Integration into TBI care pathways. The single most impactful change would be adding comprehensive binocular vision assessment to standard post-TBI evaluation protocols — in emergency departments, concussion clinics, and primary care. This requires nothing more than awareness and referral relationships. Every TBI patient whose visual symptoms are correctly identified becomes a potential therapy patient.

Insurance coverage expansion. The VA model demonstrates that covering neuro-optometric rehabilitation is economically rational when you account for reduced long-term disability costs, faster return to work, and fewer downstream healthcare encounters for symptom management. Private payers will follow when the outcomes data reaches the threshold they require — and that data is accumulating rapidly.

Telehealth and hybrid models. The shift to hybrid care models — in-person evaluation and supervised sessions combined with home-based digital reinforcement — can dramatically extend provider reach. A neuro-optometrist in a metropolitan center could supervise therapy for patients across a multi-state region, with local optometrists handling hands-on components.

Training pipeline expansion. Residency programs in neuro-optometric rehabilitation need to scale. The demand will support it. A newly graduated optometrist choosing between general practice and neuro-optometric specialization should see the market data: a served market that captures perhaps 5 percent of addressable demand, growing awareness driving referrals, and a patient population that is not going to shrink.

The vision therapy market for TBI is not speculative. The patients exist today — 2.5 million new ones every year in the US alone. The evidence is published. The treatment protocols are established. What is missing is the infrastructure to connect patients to providers at scale. Whoever builds that infrastructure is not entering a market. They are creating one.

This is the third article in a five-part series examining the vision therapy market. Read the series overview: "The Vision Therapy Market Is Bigger Than Anyone Thinks."